ELI Lilly AND
ELI LILLY AND COMPANY
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$65.2B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
23.6%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★★★★★position among all companies
23.2%
Capital efficiency
★★★★★position among all companies
77.8%
Revenue and profit
Performance, financial position and capital allocation
ELI Lilly AND
Recent performance trends
ELI Lilly AND
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$28.3 billion | US$28.5 billion | US$34.1 billion | US$45.0 billion | US$65.2 billion |
| Net income | US$5.6 billion | US$6.2 billion | US$5.2 billion | US$10.6 billion | US$20.6 billion |
| Total assets | US$48.8 billion | US$49.5 billion | US$64.0 billion | US$78.7 billion | US$112.5 billion |
| Shareholders' equity | US$9.0 billion | US$10.6 billion | US$10.8 billion | US$14.3 billion | US$26.5 billion |
| Net cash provided by (used in) operating activities | US$7.4 billion | US$7.6 billion | US$4.2 billion | US$8.8 billion | US$16.8 billion |
| Net cash provided by (used in) investing activities | US$-2.9 billion | US$-3.8 billion | US$-7.2 billion | US$-9.3 billion | US$-11.0 billion |
| Net cash provided by (used in) financing activities | US$-4.1 billion | US$-5.4 billion | US$3.5 billion | US$1.2 billion | US$-2.2 billion |
| Cash and cash equivalents | US$3.8 billion | US$2.1 billion | US$2.8 billion | US$3.3 billion | US$7.3 billion |
Revenue scale in the same industry
ELI Lilly AND
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDThis companyFY Dec 2025 US$65.2B
- 4 Merck & CoFY Dec 2025 US$65.0B
- 5 PfizerFY Dec 2025 US$62.6B
- … 51 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Cash and cash equivalents | US$7.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-2.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-11.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$16.8 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$2.0 billion | Consolidated | Disclosed |
| Dividends paid | US$5.4 billion | Consolidated | Disclosed |
| Net assets | US$26.5 billion | Consolidated | Disclosed |
| Net sales | US$65.2 billion | Consolidated | Disclosed |
| Net income | US$20.6 billion | Consolidated | Disclosed |
| Total assets | US$112.5 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$4.1 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 23.6% | Consolidated | Calculated |
| Net margin | 31.7% | Consolidated | Calculated |
| Return on equity | 77.8% | Consolidated | Calculated |